{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:05:08Z","timestamp":1794287108486,"version":"4.9.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00805-y","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:39:21Z","timestamp":1756712361000},"page":"1827-1844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antiseizure Medications and Bone Health"],"prefix":"10.1007","volume":"14","author":[{"given":"Paula V.","family":"Gaete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Cuellar-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-4206","authenticated-orcid":false,"given":"Carlos O.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"Suppl 1","key":"805_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1528-1167.2008.01443.x","volume":"49","author":"WA Hauser","year":"2008","unstructured":"Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49(Suppl 1):8\u201312.","journal-title":"Epilepsia"},{"key":"805_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/npr2.12196","volume":"41","author":"T Hakami","year":"2021","unstructured":"Hakami T. Neuropharmacology of antiseizure drugs. Neuropsychopharmacol Rep. 2021;41:336\u201351.","journal-title":"Neuropsychopharmacol Rep"},{"key":"805_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475\u201382.","journal-title":"Epilepsia"},{"key":"805_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","volume":"18","author":"GBD 2016 Epilepsy Collaborators","year":"2019","unstructured":"GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:357\u201375.","journal-title":"Lancet Neurol"},{"key":"805_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/CON.0000000000001104","volume":"28","author":"BW Abou-Khalil","year":"2022","unstructured":"Abou-Khalil BW. Update on antiseizure medications 2022. Continuum (Minneap Minn). 2022;28:500\u201335.","journal-title":"Continuum (Minneap Minn)"},{"key":"805_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101755","volume":"36","author":"NB Andersen","year":"2022","unstructured":"Andersen NB, J\u00f8rgensen NR. Impaired bone health as a co-morbidity of epilepsy. Best Pract Res Clin Rheumatol. 2022;36:101755.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"805_CR7","first-page":"272","volume-title":"Greenspan\u2019s basic and clinical endocrinology","author":"DG Gardner","year":"2018","unstructured":"Gardner DG, Shoback D. Greenspan\u2019s basic and clinical endocrinology. 10th ed. New York: McGraw Hill; 2018. p. 272\u20135.","edition":"10"},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jcp.2007.048868","volume":"61","author":"HK Datta","year":"2008","unstructured":"Datta HK, Ng WF, Walker JA, et al. The cell biology of bone metabolism. J Clin Pathol. 2008;61:577\u201387.","journal-title":"J Clin Pathol"},{"key":"805_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/421746","volume":"2015","author":"R Florencio-Silva","year":"2015","unstructured":"Florencio-Silva R, Sasso GR, Sasso-Cerri E, Sim\u00f5es MJ, Cerri PS. Biology of bone tisue: structure, function, and factors that influence bone cells. Biomed Res Int. 2015;2015:421746.","journal-title":"Biomed Res Int"},{"key":"805_CR10","first-page":"23","volume-title":"Metabolic bone disease","author":"MJ Glimcher","year":"1998","unstructured":"Glimcher MJ. The nature of the mineral phase in bone. In: Glimcher MJ, editor. Metabolic bone disease. San Diego: Academic; 1998. p. 23\u201350."},{"key":"805_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-pathmechdis-031521-040919","volume":"18","author":"DJ Veis","year":"2023","unstructured":"Veis DJ, O\u2019Brien CA. Osteoclasts, master sculptors of bone. Annu Rev Pathol. 2023;18:257\u201381.","journal-title":"Annu Rev Pathol"},{"key":"805_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10747","volume":"7","author":"JH Kim","year":"2023","unstructured":"Kim JH, Kim SY, Park JE, et al. Nationwide trends in osteoporosis in Koreans with disabilities from 2008 to 2017. JBMR Plus. 2023;7:e10747.","journal-title":"JBMR Plus"},{"key":"805_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamaneurol.2023.1580","volume":"80","author":"CB Josephson","year":"2023","unstructured":"Josephson CB, Gonzalez-Izquierdo A, Denaxas S, et al. Independent associations of incident epilepsy and enzyme-inducing and non-enzyme-inducing antiseizure medications with the development of osteoporosis. JAMA Neurol. 2023;80:843\u201350.","journal-title":"JAMA Neurol"},{"key":"805_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1600-0404.2005.00474.x","volume":"112","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P. Epilepsy, osteoporosis and fracture risk\u2014a meta-analysis. Acta Neurol Scand. 2005;112:277\u201386.","journal-title":"Acta Neurol Scand"},{"key":"805_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/epi.13603","volume":"58","author":"F Levira","year":"2017","unstructured":"Levira F, Thurman DJ, Sander JW, et al. Premature mortality of epilepsy in low- and middle-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017;58:6\u201316.","journal-title":"Epilepsia"},{"key":"805_CR16","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/j.1528-1167.2007.01161.x","volume":"48","author":"R Kobau","year":"2007","unstructured":"Kobau R, Zahran H, Grant D, et al. Prevalence of active epilepsy and health-related quality of life among adults with self-reported epilepsy in California: California Health Interview Survey, 2003. Epilepsia. 2007;48:1904\u201313.","journal-title":"Epilepsia"},{"key":"805_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2008.03.002","volume":"43","author":"GEH Fuleihan","year":"2008","unstructured":"Fuleihan GEH, Dib L, Yamout B, et al. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. 2008;43:149\u201355.","journal-title":"Bone"},{"key":"805_CR18","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1016\/S0021-9258(18)32319-6","volume":"258","author":"E Sigel","year":"1983","unstructured":"Sigel E, Stephenson FA, Mamalaki C, et al. A gamma-aminobutyric acid\/benzodiazepine receptor complex of bovine cerebral cortex. J Biol Chem. 1983;258:6965\u201371.","journal-title":"J Biol Chem"},{"key":"805_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ana.410250302","volume":"25","author":"RE Twyman","year":"1989","unstructured":"Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989;25:213\u201320.","journal-title":"Ann Neurol"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0022-3565(25)05235-8","volume":"108","author":"LS Goodman","year":"1953","unstructured":"Goodman LS, Swinyard EA, Brown WC, et al. Anticonvulsant properties of 5-phenyl-5-ethyl-hexahydropyrimidine-4,6-dione (mysoline), a new antiepileptic. J Pharmacol Exp Ther. 1953;108:428\u201336.","journal-title":"J Pharmacol Exp Ther"},{"key":"805_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1471-4159.1977.tb10721.x","volume":"29","author":"MJ Jung","year":"1977","unstructured":"Jung MJ, Lippert B, Metcalf BW, et al. gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977;29:797\u2013802.","journal-title":"J Neurochem"},{"key":"805_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1471-4159.1990.tb01919.x","volume":"54","author":"C Braestrup","year":"1990","unstructured":"Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem. 1990;54:639\u201347.","journal-title":"J Neurochem"},{"key":"805_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1684\/epd.2011.0444","volume":"13","author":"LL Zhang","year":"2011","unstructured":"Zhang LL, Zeng LN, Li YP. Side effects of phenobarbital in epilepsy: a systematic review. Epileptic Disord. 2011;13:349\u201365.","journal-title":"Epileptic Disord"},{"key":"805_CR24","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","volume":"106","author":"H Daneshvar","year":"1999","unstructured":"Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106:1792\u20138.","journal-title":"Ophthalmology"},{"key":"805_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","volume":"67","author":"MC Lawden","year":"1999","unstructured":"Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716\u201322.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"805_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/eye.2008.139","volume":"22","author":"MJ Hawker","year":"2008","unstructured":"Hawker MJ, Astbury NJ. The ocular side effects of vigabatrin (Sabril): information and guidance for screening. Eye (Lond). 2008;22:1097\u20138.","journal-title":"Eye (Lond)"},{"key":"805_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/15357597231225065","volume":"24","author":"S Eyal","year":"2024","unstructured":"Eyal S. Tuning sodium channel blockers to the near-atomic level. Epilepsy Curr. 2024;24:123\u20135.","journal-title":"Epilepsy Curr"},{"key":"805_CR28","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/epi.14591","volume":"59","author":"EP Borrelli","year":"2018","unstructured":"Borrelli EP, Lee EY, Descoteaux AM, et al. Stevens\u2013Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;59:2318\u201324.","journal-title":"Epilepsia"},{"key":"805_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","volume":"77","author":"J Vidaurre","year":"2017","unstructured":"Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23\u201336.","journal-title":"Pediatr Neurol"},{"key":"805_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.seizure.2017.03.013","volume":"48","author":"DA Pitetzis","year":"2017","unstructured":"Pitetzis DA, Spilioti MG, Yovos JG, et al. The effect of VPA on bone: from clinical studies to cell culture: the molecular mechanisms revisited. Seizure. 2017;48:36\u201343.","journal-title":"Seizure"},{"key":"805_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJM198003203021204","volume":"302","author":"J Koch-Weser","year":"1980","unstructured":"Koch-Weser J, Browne TR. Drug therapy: valproic acid. N Engl J Med. 1980;302:661\u20136.","journal-title":"N Engl J Med"},{"key":"805_CR32","volume":"1","author":"F Brigo","year":"2021","unstructured":"Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2021;1:CD003032.","journal-title":"Cochrane Database Syst Rev"},{"key":"805_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW, Striessnig J, Koschak A, et al. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67:821\u201370.","journal-title":"Pharmacol Rev"},{"key":"805_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","volume":"16","author":"EP Calandre","year":"2016","unstructured":"Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16:1263\u201377.","journal-title":"Expert Rev Neurother"},{"key":"805_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neulet.2012.03.056","volume":"518","author":"K Fukuyama","year":"2012","unstructured":"Fukuyama K, Tanahashi S, Nakagawa M, et al. Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett. 2012;518:69\u201374.","journal-title":"Neurosci Lett"},{"key":"805_CR36","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","volume":"154","author":"A Matagne","year":"2008","unstructured":"Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154:1662\u201371.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 4","key":"805_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1528-1167.2001.00007.x","volume":"42","author":"M Privitera","year":"2001","unstructured":"Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia. 2001;42(Suppl 4):31\u20135.","journal-title":"Epilepsia"},{"key":"805_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","volume":"87","author":"E Ben-Menachem","year":"2016","unstructured":"Ben-Menachem E, Mameni\u0161kien\u0117 R, Quarato PP. Efficacy and safety of brivaracetam for partial onset seizures in 3 pooled clinical studies. Neurology. 2016;87:314\u201323.","journal-title":"Neurology"},{"key":"805_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/epi.17843","volume":"65","author":"R Roberti","year":"2024","unstructured":"Roberti R, Di Gennaro G, Anzellotti F, et al. A real-world comparison among third-generation antiseizure medications: results from the compare study. Epilepsia. 2024;65:456\u201372.","journal-title":"Epilepsia"},{"issue":"S1","key":"805_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1684\/epd.2020.1135","volume":"22","author":"RA Gray","year":"2020","unstructured":"Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10\u20135.","journal-title":"Epileptic Disord"},{"issue":"111","key":"805_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.neuron.2023.01.018","volume":"19","author":"EC Rosenberg","year":"2023","unstructured":"Rosenberg EC, Chamberland S, Bazelot M, et al. Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity. Neuron. 2023;19(111):1282\u2013300.","journal-title":"Neuron"},{"key":"805_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/can.2019.0028","volume":"5","author":"RA Gray","year":"2020","unstructured":"Gray RA, Stott CG, Jones NJ, et al. Anticonvulsive properties of cannabidiol (CBD) in a model of generalized seizure are transient receptor potential vanilloid 1 (TRPV1) dependent. Cannabis Cannabinoid Res. 2020;5:145\u20139.","journal-title":"Cannabis Cannabinoid Res"},{"key":"805_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele EA, Bebin EM, Bhathal H, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78:285\u201392.","journal-title":"JAMA Neurol"},{"key":"805_CR44","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011\u201320.","journal-title":"N Engl J Med"},{"key":"805_CR45","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888\u201397.","journal-title":"N Engl J Med"},{"key":"805_CR46","volume":"2","author":"J Pulman","year":"2014","unstructured":"Pulman J, Jette N, Dykeman J, et al. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014;2:CD001417.","journal-title":"Cochrane Database Syst Rev"},{"key":"805_CR47","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1007\/s12325-023-02586-y","volume":"40","author":"NZ Pearl","year":"2023","unstructured":"Pearl NZ, Babin CP, Catalano NT, et al. Narrative review of topiramate: clinical uses and pharmacological considerations. Adv Ther. 2023;40:3626\u201338.","journal-title":"Adv Ther"},{"key":"805_CR48","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327:1269\u201381.","journal-title":"JAMA"},{"key":"805_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000443535","volume":"68","author":"X He","year":"2016","unstructured":"He X, Jiang P, Zhu W, et al. Effect of antiepileptic therapy on serum 25(OH)D3 and 24,25(OH)2D3 levels in epileptic children. Ann Nutr Metab. 2016;68:119\u201327.","journal-title":"Ann Nutr Metab"},{"key":"805_CR50","first-page":"E55","volume":"245","author":"DT Baran","year":"1983","unstructured":"Baran DT. Effect of phenobarbital treatment on metabolism of vitamin\u00a0D by rat liver. Am J Physiol. 1983;245:E55\u20139.","journal-title":"Am J Physiol"},{"key":"805_CR51","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1172\/JCI106868","volume":"51","author":"TJ Hahn","year":"1972","unstructured":"Hahn TJ, Birge SJ, Scharp CR, et al. Phenobarbital-induced alterations in vitamin\u00a0D metabolism. J Clin Investig. 1972;51:741\u20138.","journal-title":"J Clin Investig"},{"key":"805_CR52","volume":"14","author":"T Branco","year":"2022","unstructured":"Branco T, Cardoso A, Baltazar A, et al. Loss of seizure control in a patient with vitamin\u00a0D deficiency and phenytoin-induced hypocalcemia. Cureus. 2022;14:e32407.","journal-title":"Cureus"},{"key":"805_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106829","volume":"178","author":"C LoPinto-Khoury","year":"2021","unstructured":"LoPinto-Khoury C, Brennan L, Mintzer S. Impact of carbamazepine on vitamin\u00a0D levels: a meta-analysis. Epilepsy Res. 2021;178:106829.","journal-title":"Epilepsy Res"},{"key":"805_CR54","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1528-1167.2006.00460.x","volume":"47","author":"S Mintzer","year":"2006","unstructured":"Mintzer S, Boppana P, Toguri J, et al. Vitamin\u00a0D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47:510\u20135.","journal-title":"Epilepsia"},{"key":"805_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/07315724.1984.10720035","volume":"3","author":"M Gascon-Barr\u00e9","year":"1984","unstructured":"Gascon-Barr\u00e9 M, Villeneuve JP, Lebrun LH. Effect of increasing doses of phenytoin on the plasma 25-hydroxyvitamin\u00a0D and 1,25-dihydroxyvitamin\u00a0D concentrations. J Am Coll Nutr. 1984;3:45\u201350.","journal-title":"J Am Coll Nutr"},{"key":"805_CR56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5455\/medarh.2018.72.262-266","volume":"72","author":"EM Suljic","year":"2018","unstructured":"Suljic EM, Mehicevic A, Mahmutbegovic N. Effect of long-term carbamazepine therapy on bone health. Med Arch. 2018;72:262\u20136.","journal-title":"Med Arch"},{"key":"805_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.seizure.2015.02.022","volume":"28","author":"S Svalheim","year":"2015","unstructured":"Svalheim S, Sveberg L, Mochol M, et al. Interactions between antiepileptic drugs and hormones. Seizure. 2015;28:12\u20137.","journal-title":"Seizure"},{"key":"805_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/ana.410050411","volume":"5","author":"RD Bell","year":"1979","unstructured":"Bell RD, Pak CY, Zerwekh J, et al. Effect of phenytoin on bone and vitamin\u00a0D metabolism. Ann Neurol. 1979;5:374\u20138.","journal-title":"Ann Neurol"},{"key":"805_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-0404.1984.tb00806.x","volume":"70","author":"V Hoikka","year":"1984","unstructured":"Hoikka V, Alhava EM, Karjalainen P, et al. Carbamazepine and bone mineral metabolism. Acta Neurol Scand. 1984;70:77\u201380.","journal-title":"Acta Neurol Scand"},{"key":"805_CR60","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1046\/j.1528-1157.2002.13002.x","volume":"43","author":"A Verrotti","year":"2002","unstructured":"Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43:1488\u201392.","journal-title":"Epilepsia"},{"key":"805_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40263-024-01137-5","volume":"39","author":"Y Novitskaya","year":"2025","unstructured":"Novitskaya Y, Schulze-Bonhage A, Sch\u00fctz E, et al. Effects of one-year anti-seizure treatment with add-on cenobamate on bone density and bone turnover in adults with drug-resistant focal epilepsy: an observational study. CNS Drugs. 2025;39:95\u2013106.","journal-title":"CNS Drugs"},{"key":"805_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2019.106216","volume":"158","author":"S Mintzer","year":"2019","unstructured":"Mintzer S, Constantino T, Gidal B, Bhargava P, Grinnell T, Blum D. Markers of bone and lipid metabolism with eslicarbazepine acetate monotherapy. Epilepsy Res. 2019;158:106216.","journal-title":"Epilepsy Res"},{"key":"805_CR63","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40263-023-01045-0","volume":"37","author":"M Hirsch","year":"2023","unstructured":"Hirsch M, Immisch I, Knake S, et al. A prospective longitudinal study of the effects of eslicarbazepine acetate treatment on bone density and metabolism in patients with focal-onset epilepsy. CNS Drugs. 2023;37:973\u201380.","journal-title":"CNS Drugs"},{"key":"805_CR64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0404.2008.01148.x","volume":"120","author":"Y Cetinkaya","year":"2009","unstructured":"Cetinkaya Y, Kurtulmu\u015f YS, Tutkavul K, et al. The effect of oxcarbazepine on bone metabolism. Acta Neurol Scand. 2009;120:170\u20135.","journal-title":"Acta Neurol Scand"},{"key":"805_CR65","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.eplepsyres.2013.09.009","volume":"108","author":"DL Koo","year":"2014","unstructured":"Koo DL, Hwang KJ, Han SW. Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2014;108:442\u20137.","journal-title":"Epilepsy Res"},{"key":"805_CR66","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/nu14132673","volume":"14","author":"M Moreno-Torres","year":"2022","unstructured":"Moreno-Torres M, Guzm\u00e1n C, Petrov PD, Jover R. Valproate and short-chain fatty acids activate transcription of the human vitamin\u00a0D receptor gene through a proximal GC-rich DNA region containing two putative Sp1 binding sites. Nutrients. 2022;14:2673.","journal-title":"Nutrients"},{"key":"805_CR67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.toxlet.2010.11.008","volume":"200","author":"R Vrzal","year":"2011","unstructured":"Vrzal R, Doricakova A, Novotna A, et al. Valproic acid augments vitamin\u00a0D receptor-mediated induction of CYP24 by vitamin\u00a0D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett. 2011;200:146\u201353.","journal-title":"Toxicol Lett"},{"key":"805_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41392-023-01726-8","volume":"9","author":"X Xie","year":"2024","unstructured":"Xie X, Cheng P, Hu L, et al. Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss. Signal Transduct Target Ther. 2024;9:24.","journal-title":"Signal Transduct Target Ther"},{"key":"805_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1139\/cjpp-2013-0504","volume":"92","author":"MJ Anwar","year":"2014","unstructured":"Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not levetiracetam induce bone alterations in female mice. Can J Physiol Pharmacol. 2014;92:507\u201311.","journal-title":"Can J Physiol Pharmacol"},{"key":"805_CR70","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eplepsyres.2013.06.011","volume":"106","author":"EL Humphrey","year":"2013","unstructured":"Humphrey EL, Morris GE, Fuller HR. Valproate reduces collagen and osteonectin in cultured bone cells. Epilepsy Res. 2013;106:446\u201350.","journal-title":"Epilepsy Res"},{"key":"805_CR71","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/stem.1544","volume":"32","author":"F Paino","year":"2014","unstructured":"Paino F, La Noce M, Tirino V, et al. Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells. 2014;32:279\u201389.","journal-title":"Stem Cells"},{"key":"805_CR72","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.3390\/ijms21207513","volume":"21","author":"T Komori","year":"2020","unstructured":"Komori T. Functions of osteocalcin in bone, pancreas, testis, and muscle. Int J Mol Sci. 2020;21:7513.","journal-title":"Int J Mol Sci"},{"key":"805_CR73","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.tiv.2007.09.004","volume":"22","author":"NW Jacobsen","year":"2008","unstructured":"Jacobsen NW, Halling-S\u00f8rensen B, Birkved FK. Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. Toxicol In Vitro. 2008;22:146\u201353.","journal-title":"Toxicol In Vitro"},{"key":"805_CR74","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s43440-020-00087-1","volume":"72","author":"SS Diemar","year":"2020","unstructured":"Diemar SS, Sejling AS, Eiken P, et al. Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats. Pharmacol Rep. 2020;72:1323\u201333.","journal-title":"Pharmacol Rep"},{"key":"805_CR75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yebeh.2015.12.025","volume":"55","author":"AK Artemiadis","year":"2016","unstructured":"Artemiadis AK, Lambrinoudaki I, Voskou P, et al. Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. Epilepsy Behav. 2016;55:84\u20136.","journal-title":"Epilepsy Behav"},{"key":"805_CR76","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1111\/epi.12162","volume":"54","author":"K Phabphal","year":"2013","unstructured":"Phabphal K, Geater A, Limapichat K, et al. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25\u00a0hydroxyvitamin\u00a0D, and parathyroid hormone in young adult patients with epilepsy. Epilepsia. 2013;54:e94\u20138.","journal-title":"Epilepsia"},{"key":"805_CR77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","volume":"13","author":"BK Beyreuther","year":"2007","unstructured":"Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13:21\u201342.","journal-title":"CNS Drug Rev"},{"key":"805_CR78","first-page":"148","volume":"22","author":"ZN Cheng","year":"2001","unstructured":"Cheng ZN, Shu Y, Liu ZQ, et al. Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001;22:148\u201354.","journal-title":"Acta Pharmacol Sin"},{"key":"805_CR79","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2220\/biomedres.38.297","volume":"38","author":"J Kanda","year":"2017","unstructured":"Kanda J, Izumo N, Kobayashi Y, et al. Effects of the antiepileptic drugs topiramate and lamotrigine on bone metabolism in rats. Biomed Res. 2017;38:297\u2013305.","journal-title":"Biomed Res"},{"key":"805_CR80","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ana.20378","volume":"57","author":"AM Pack","year":"2005","unstructured":"Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol. 2005;57:252\u20137.","journal-title":"Ann Neurol"},{"key":"805_CR81","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.eplepsyres.2016.10.005","volume":"128","author":"J Simko","year":"2016","unstructured":"Simko J, Karesova I, Kremlacek J, et al. The effect of lamotrigine and phenytoin on bone turnover and bone strength: a prospective study in Wistar rats. Epilepsy Res. 2016;128:113\u20138.","journal-title":"Epilepsy Res"},{"key":"805_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107489","volume":"113","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lin Z, Huang Y, Yu L. Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy. Epilepsy Behav. 2020;113:107489.","journal-title":"Epilepsy Behav"},{"key":"805_CR83","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pediatrneurol.2007.05.018","volume":"37","author":"RD Sheth","year":"2007","unstructured":"Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol. 2007;37:250\u20134.","journal-title":"Pediatr Neurol"},{"key":"805_CR84","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/j.1528-1167.2011.03131.x","volume":"52","author":"K Heo","year":"2011","unstructured":"Heo K, Rhee Y, Lee HW, et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia. 2011;52:1884\u20139.","journal-title":"Epilepsia"},{"key":"805_CR85","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1528-1157.1999.tb00781.x","volume":"40","author":"A Wilner","year":"1999","unstructured":"Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia. 1999;40:792\u20135.","journal-title":"Epilepsia"},{"key":"805_CR86","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1248\/bpb.b17-00482","volume":"40","author":"J Kanda","year":"2017","unstructured":"Kanda J, Izumo N, Kobayashi Y, et al. Effects of the antiepileptic drugs phenytoin, gabapentin, and levetiracetam on bone strength, bone mass, and bone turnover in rats. Biol Pharm Bull. 2017;40:1934\u201340.","journal-title":"Biol Pharm Bull"},{"key":"805_CR87","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jocd.2021.05.001","volume":"25","author":"B Akin","year":"2022","unstructured":"Akin B, Kelle B, Kozanoglu E. The effect of pregabalin on bone metabolism. J Clin Densitom. 2022;25:223\u20139.","journal-title":"J Clin Densitom"},{"key":"805_CR88","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/sj.bjp.0707593","volume":"153","author":"I Bab","year":"2008","unstructured":"Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008;153:182\u20138.","journal-title":"Br J Pharmacol"},{"key":"805_CR89","doi-asserted-by":"publisher","first-page":"405","DOI":"10.15283\/ijsc21152","volume":"15","author":"L Li","year":"2022","unstructured":"Li L, Feng J, Sun L, et al. Cannabidiol promotes osteogenic differentiation of bone marrow mesenchymal stem cells in the inflammatory microenvironment via the CB2-dependent p38 MAPK signaling pathway. Int J Stem Cells. 2022;15:405\u201314.","journal-title":"Int J Stem Cells"},{"key":"805_CR90","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00223-023-01083-2","volume":"112","author":"R Ihejirika-Lomedico","year":"2023","unstructured":"Ihejirika-Lomedico R, Patel K, Buchalter DB, et al. Non-psychoactive cannabidiol prevents osteoporosis in an animal model and increases cell viability, proliferation, and osteogenic gene expression in human skeletal stem and progenitor cells. Calcif Tissue Int. 2023;112:716\u201326.","journal-title":"Calcif Tissue Int"},{"key":"805_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.900667","volume":"13","author":"K Sui","year":"2022","unstructured":"Sui K, Tveter KM, Bawagan FG, et al. Cannabidiol-treated ovariectomized mice show improved glucose, energy, and bone metabolism with a bloom in lactobacillus. Front Pharmacol. 2022;13:900667.","journal-title":"Front Pharmacol"},{"key":"805_CR92","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.3390\/ijms22137162","volume":"22","author":"A Matuszewska","year":"2021","unstructured":"Matuszewska A, Nowak B, Nikodem A, et al. Antiepileptic stiripentol may influence bones. Int J Mol Sci. 2021;22:7162.","journal-title":"Int J Mol Sci"},{"key":"805_CR93","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11010-005-8159-6","volume":"273","author":"T Tamayama","year":"2005","unstructured":"Tamayama T, Maemura K, Kanbara K, et al. Expression of GABA(A) and GABA(B) receptors in rat growth plate chondrocytes: activation of the GABA receptors promotes proliferation of mouse chondrogenic ATDC5 cells. Mol Cell Biochem. 2005;273:117\u201326.","journal-title":"Mol Cell Biochem"},{"key":"805_CR94","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/epi.16678","volume":"61","author":"DL Koo","year":"2020","unstructured":"Koo DL, Nam H. Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients. Epilepsia. 2020;61:2142\u20139.","journal-title":"Epilepsia"},{"key":"805_CR95","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000529970","volume":"108","author":"I Karesova","year":"2023","unstructured":"Karesova I, Simko J, Fekete S, et al. The effect of zonisamide on rat bone mass, structure, and metabolism. Pharmacology. 2023;108:359\u201367.","journal-title":"Pharmacology"},{"key":"805_CR96","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/GRF.0b013e3182a9d15a","volume":"56","author":"MS Christianson","year":"2013","unstructured":"Christianson MS, Shen W. Osteoporosis prevention and management: nonpharmacologic and lifestyle options. Clin Obstet Gynecol. 2013;56:703\u201310.","journal-title":"Clin Obstet Gynecol"},{"key":"805_CR97","unstructured":"Zaheer S, LeBoff MS. Osteoporosis: prevention and treatment. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth: MDText.com, Inc.; 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279073\/."},{"key":"805_CR98","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2021 (SIGN publication no. 142). http:\/\/www.sign.ac.uk"},{"key":"805_CR99","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.eprac.2024.04.013","volume":"30","author":"FP Chen","year":"2024","unstructured":"Chen FP, Lin YC, Lin YJ, et al. Relationship between serum 25-hydroxyvitamin\u00a0D and bone mineral density, fracture risk, and bone metabolism in adults with osteoporosis\/fractures. Endocr Pract. 2024;30:616\u201323.","journal-title":"Endocr Pract"},{"key":"805_CR100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40795-023-00707-y","volume":"9","author":"A Khodabakhshi","year":"2023","unstructured":"Khodabakhshi A, Davoodi SH, Vahid F. Vitamin\u00a0D status, including serum levels and sun exposure are associated or correlated with bone mass measurements diagnosis, and bone density of the spine. BMC Nutr. 2023;9:48.","journal-title":"BMC Nutr"},{"key":"805_CR101","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin\u00a0D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"805_CR102","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/epi.14015","volume":"59","author":"H Fernandez","year":"2018","unstructured":"Fernandez H, Mohammed HT, Patel T. Vitamin\u00a0D supplementation for bone health in adults with epilepsy: a systematic review. Epilepsia. 2018;59:885\u201396.","journal-title":"Epilepsia"},{"key":"805_CR103","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1528-1167.2006.00507.x","volume":"47","author":"CL Harden","year":"2006","unstructured":"Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447\u201351.","journal-title":"Epilepsia"},{"key":"805_CR104","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00198-016-3773-6","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, Biver E, Kaufman JM, et al. The role of calcium supplementation in healthy musculoskeletal ageing: an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2017;28:447\u201362.","journal-title":"Osteoporos Int"},{"issue":"2","key":"805_CR105","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00198-006-0185-z","volume":"18","author":"SJ Petty","year":"2007","unstructured":"Petty SJ, O\u2019Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int. 2007;18(2):129\u201342.","journal-title":"Osteoporos Int"},{"key":"805_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3427","volume":"344","author":"J Hippisley-Cox","year":"2012","unstructured":"Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344:e3427.","journal-title":"BMJ"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00805-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:03:07Z","timestamp":1758369787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00805-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00805-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paula V. Gaete, Valentina Cuellar-Rodr\u00edguez and Carlos O. Mendivil have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}